The US Oncology Network

Kat M. Aguilar, MPH, discussed findings on social determinants of health and cancer mortality and their practical implications for community oncology.

Neel Shah, MD, our first 2025 Oncology Icon, reflected on his journey from academic medicine to community oncology.

Kat M. Aguilar, MPH, discussed the findings of the recent study evaluating the early adoption of the distress thermometer.

Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.

ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.

Andrea Roman, PharmD, BCOP, US Oncology Network and McKesson, discussed the integration of clinical pharmacists into community oncology practices.

Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care.

Designation enables providers to report meaningful, oncology-specific quality measures for participation in the Merit-based Incentive Payment System

Results show a 70 percent knowledge improvement and an improved retention rate.

The study of rare cancers has undergone a paradigm shift, transitioning from a singular disease entity approach to a more nuanced understanding of biomarker-defined subtypes.

Jeff Sharman, MD, discusses the clinical implications for oncologists based on data from the ELEVATE-TN trial.

The knowledge gained from biomarker testing can help develop cancer prevention, diagnosis, and treatment strategies that specifically target a person’s cancer subtype.

As gene editing technology continues to advance, it could fundamentally change the landscape of cancer treatment.

Ira Zackon, MD, explains how clinicians can ensure clinical trial patient populations are more inclusive and minorities are better represented.

Jeff Sharman, MD, discusses findings from the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for the treatment of patients with treatment-naive chronic lymphocytic leukemia.

Ira Zackon, MD, discusses what strategies community oncology practices can implement to address racial and socioeconomic disparities in chronic lymphocytic leukemia.

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

Cancer care disparities exist for underrepresented groups due to limited access to healthcare, clinical trials, and cultural barriers, but solutions like telemedicine and improved communication are emerging.

Tennessee Cancer Specialists, the third largest oncology practice in the state, strengthens its ability to deliver cutting-edge advanced care by joining The Network.

Daniel Rubin, PharmD, discusses key takeaways from a study exploring the use. of a clinical decision tool for biomarker documentation.

Jessica Paulus, ScD, discussed a study investigating real-world trends in lung cancer staging among community oncology practices.

Andrea Roman, PharmD, BCOP, discusses findings from a study investigating the benefits of remote oncology pharmacists.

Puneeth Indurlal, MD, MS, discusses the implications of assessing for patients' health-related social needs during the course of cancer treatment at the 2024 ASCO Annual Meeting.

Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.

Ira Zackon, MD, discusses the background of a real-world study which sought to identify some of the racial and socioeconomic disparities seen in patients with chronic lymphocytic leukemia.

Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

Debra Patt, MD, PhD, MBA, discussed the ways oncologists can ensure a bright future for themselves and their patients through embracing technology.

In an interview with Targeted Oncology, Robert Reid, MD, discussed how the utilization of Ontada’s solutions helps to improve community-based research across the field of oncology.